In 85 patients undergoing laparoscopic surgery for benign adnexal tumors, higher BMI was linked to increased abdominal wall thickness but did not significantly prolong primary trocar insertion using the open technique. Complication rates were comparable, highlighting the role of surgical experience.
As obesity care continues to evolve, clinical focus is shifting from initiating therapy to managing obesity as a long-term, relapsing condition. Recent advances in oral glucagon-like peptide-1 (GLP-1) receptor agonist development reinforce this shift, prompting clinicians to consider not only whether to use pharmacologic therapy, but how it can be integrated into sustained, multidimensional care plans over time.
GLP-1 receptor activation influences appetite regulation, satiety signaling, and metabolic pathways central to obesity pathophysiology. Oral formulations demonstrate that these mechanisms can be engaged through daily administration, expanding how clinicians think about treatment design and long-term engagement. This evolution brings renewed attention to clinical integration—how pharmacologic therapy aligns with behavioral strategies, lifestyle interventions, and ongoing monitoring rather than functioning as a stand-alone solution.
Patient selection and adherence remain central considerations in long-term obesity management. Functional factors such as daily dosing routines, gastrointestinal tolerability, and treatment fatigue—as well as emotional factors including expectations, motivation, and prior weight-loss experiences—may influence sustained use and outcomes. These considerations highlight the importance of shared decision-making and regular reassessment as patient needs and priorities evolve.
Rather than viewing therapy choice as a single decision point, many clinicians are approaching obesity care as a dynamic process that requires adjustment over time. Evidence-based strategies increasingly emphasize structured follow-up, realistic goal-setting, behavioral support, and coordinated, multidisciplinary care. Within this framework, oral GLP-1 approaches may offer flexibility across different phases of treatment, including escalation, stabilization, or maintenance.
What factors most influence how you select patients for long-term pharmacologic obesity therapy?As oral GLP-1 options enter clinical practice, what adherence challenges or integration considerations will most shape how you incorporate them into comprehensive obesity care?
Source : https://pubmed.ncbi.nlm.nih.gov/41769479/
Internal hernia is a recognized late complication of Roux-en-Y gastric bypass (RYGB), often occurring through mesenteric defects at the jejunojejunostomy (JJ) or Petersen's space. While most hernias result from anatomical...
Case report describes rare enteroenteric fistula–induced internal hernia causing small-bowel obstruction years after Roux-en-Y gastric bypass, successfully treated with robotic laparoscopic fistula excision and rapid postoperative recovery.
Did you know? Obesity-related systemic inflammation can reshape the tumor microenvironment and influence the efficacy and toxicity of immune checkpoint inhibitors in lung cancer. Adipokines, body composition metrics, and inflammatory biomarkers may help explain the “obesity paradox” and predict immune-related adverse events, including endocrine toxicities.
Could integrating obesity-related inflammatory biomarkers improve risk stratification and personalization of immunotherapy in lung cancer?
Could integrating obesity-related inflammatory biomarkers improve risk stratification and personalization of immunotherapy in lung cancer?
Source : https://pubmed.ncbi.nlm.nih.gov/41754837/
Introduction : Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has demonstrated unprecedented efficacy in the treatment of type 2 diabetes mellitus (T2DM) and obesity. However, its rapid clinical widespread use...
This review finds semaglutide maintains a favorable benefit-risk profile, with no confirmed increased cancer risk in humans and emerging cardioprotective effects, including potential mitigation of anticancer therapy–related cardiotoxicity, warranting continued monitoring.